These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 35532095)
1. Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC). Karnik KS; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Wakte PS J Biomol Struct Dyn; 2023 Jul; 41(10):4696-4710. PubMed ID: 35532095 [TBL] [Abstract][Full Text] [Related]
2. Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624 [TBL] [Abstract][Full Text] [Related]
3. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869 [TBL] [Abstract][Full Text] [Related]
4. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519 [TBL] [Abstract][Full Text] [Related]
5. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC). Karnik KS; Sarkate AP; Tiwari SV; Azad R; Wakte PS Bioorg Chem; 2021 Oct; 115():105226. PubMed ID: 34364055 [TBL] [Abstract][Full Text] [Related]
6. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment. Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC. Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study. Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777 [TBL] [Abstract][Full Text] [Related]
10. Discovery of highly potent and selective EGFR Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818 [TBL] [Abstract][Full Text] [Related]
11. Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations. Wu X; Guo Q; Li Q; Wan S; Li Z; Zhang J J Biomol Struct Dyn; 2022 Aug; 40(13):5848-5857. PubMed ID: 33459177 [TBL] [Abstract][Full Text] [Related]
12. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S. Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819 [TBL] [Abstract][Full Text] [Related]
13. BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non small cell lung cancer (NSCLC). Patel HM; Shaikh M; Ahmad I; Lokwani D; Surana SJ J Biomol Struct Dyn; 2021 May; 39(8):2838-2856. PubMed ID: 32276580 [TBL] [Abstract][Full Text] [Related]
14. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. Chen H; Lai M; Zhang T; Chen Y; Tong L; Zhu S; Zhou Y; Ren X; Ding J; Xie H; Lu X; Ding K J Med Chem; 2022 May; 65(9):6840-6858. PubMed ID: 35446588 [TBL] [Abstract][Full Text] [Related]
15. In silico target specific design of potential quinazoline-based anti-NSCLC agents. Mohammadnejadi E; Razzaghi-Asl N J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424 [TBL] [Abstract][Full Text] [Related]
16. Identification of luteolin -7-glucoside and epicatechin gallate from Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072 [TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. Dou D; Wang J; Qiao Y; Wumaier G; Sha W; Li W; Mei W; Yang T; Zhang C; He H; Wang C; Chu L; Sun B; Su R; Ma X; Gong M; Xie L; Jiang W; Diao Y; Zhu L; Zhao Z; Chen Z; Xu Y; Li S; Li H Eur J Med Chem; 2022 Dec; 244():114856. PubMed ID: 36279692 [TBL] [Abstract][Full Text] [Related]
18. Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations. Wan S; Yan R; Jiang Y; Li Z; Zhang J; Wu X J Biomol Struct Dyn; 2019 Oct; 37(16):4384-4394. PubMed ID: 30499387 [TBL] [Abstract][Full Text] [Related]
19. Targeting EGFR Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179 [TBL] [Abstract][Full Text] [Related]
20. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]